1h Free Analyst Time
The Cell & Gene Therapy Biomanufacturing CDMO Market grew from USD 338.12 million in 2023 to USD 485.47 million in 2024. It is expected to continue growing at a CAGR of 32.53%, reaching USD 2.42 billion by 2030.Speak directly to the analyst to clarify any post sales queries you may have.
Cell and gene therapy biomanufacturing CDMOs (Contract Development and Manufacturing Organizations) represent a specialized segment within the biotechnology industry focused on the production and development of personalized therapies derived from cellular and genetic materials. The necessity of CDMOs arises from the complexity, resource intensity, and regulatory challenges associated with manufacturing these therapies. They serve as vital partners for biotech companies, offering scalable production solutions, technical expertise, and regulatory compliance support. The application scope includes a variety of therapeutic areas, notably oncology, rare genetic disorders, cardiovascular diseases, and regenerative medicine, promising significant advancements in personalized medicine. End-use markets primarily involve pharmaceutical and biotech companies, research institutions, and hospitals specializing in cutting-edge therapies. Key growth factors include heightened investment in precision medicine, expanding research and development activities, advancements in gene-editing technologies like CRISPR, and favorable regulatory pathways for orphan drugs. Notable opportunities lie in leveraging automation and digital technologies to streamline production processes, expanding capacities to meet growing demand, and establishing strategic partnerships to enhance value chains. However, the market faces several challenges, such as stringent regulatory requirements, high costs of production, and complex logistics associated with maintaining product integrity. Additionally, limited skilled workforce and technological bottlenecks could impede rapid scale-up efforts. To mitigate these issues, innovations focusing on closed system manufacturing, continuous processing, and expanding bioreactor technologies are critical. The market's nature is dynamic, characterized by rapid technological advancements and competitive pressures as companies race to commercialize viable therapies. To capitalize on growth opportunities, businesses should invest in building robust regulatory expertise, enhancing manufacturing agility through advanced technologies, and fostering collaborations with academic and research institutions. Continued focus on process standardization, cost reduction strategies, and expansion into emerging markets will also be essential to sustain growth and competitiveness in this evolving industry landscape.
Understanding Market Dynamics in the Cell & Gene Therapy Biomanufacturing CDMO Market
The Cell & Gene Therapy Biomanufacturing CDMO Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Growing number of R&D activities in cellular and genetic engineering and therapies
- Increasing need for genetic treatments to cure chronic and genetic disorders
- Rising number of collaborative activities between CDMOs and major players
- Market Restraints
- High cost of CDMO services
- Market Opportunities
- Efforts by CDMOs to incorporate digitalization and AI technologies
- Rising number of biotechnology and pharmaceutical startups
- Market Challenges
- Complex regulations surrounding genetic and cell research
Exploring Porter’s Five Forces for the Cell & Gene Therapy Biomanufacturing CDMO Market
Porter’s Five Forces framework further strengthens the insights of the Cell & Gene Therapy Biomanufacturing CDMO Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Cell & Gene Therapy Biomanufacturing CDMO Market
External macro-environmental factors deeply influence the performance of the Cell & Gene Therapy Biomanufacturing CDMO Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Cell & Gene Therapy Biomanufacturing CDMO Market
The Cell & Gene Therapy Biomanufacturing CDMO Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Cell & Gene Therapy Biomanufacturing CDMO Market
The Cell & Gene Therapy Biomanufacturing CDMO Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Cell & Gene Therapy Biomanufacturing CDMO Market
The Cell & Gene Therapy Biomanufacturing CDMO Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Cell & Gene Therapy Biomanufacturing CDMO Market, highlighting leading vendors and their innovative profiles. These include AGC Biologics, Almac Group, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Catalent Inc.,, Charles River Laboratories International Inc., Danaher Corporation, Endress+Hauser Group Services AG, FUJIFILM Diosynth Biotechnologies, GC Corporation, General Electric Company, Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Patheon Inc., PCI Pharma Services, Pfizer CentreOne, PIERRE GUERIN, Recipharm AB, Samsung Biologics, Sartorius AG, Thermo Fisher Scientific, uBriGene, WuXi Advanced Therapies, and WuXi AppTec.Market Segmentation & Coverage
This research report categorizes the Cell & Gene Therapy Biomanufacturing CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:- Component
- Cell Therapy
- Plasmid DNA
- Viral Vector
- Phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Indication
- Cancer
- Cardiovascular Disease
- Genetic Disorders
- Infectious Disease
- Neurological Disorders
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Cell & Gene Therapy Biomanufacturing CDMO Market, by Component
7. Cell & Gene Therapy Biomanufacturing CDMO Market, by Phase
8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Indication
9. Americas Cell & Gene Therapy Biomanufacturing CDMO Market
10. Asia-Pacific Cell & Gene Therapy Biomanufacturing CDMO Market
11. Europe, Middle East & Africa Cell & Gene Therapy Biomanufacturing CDMO Market
12. Competitive Landscape
LIST OF FIGURES
LIST OF TABLES
Companies Mentioned
The leading players in the Cell & Gene Therapy Biomanufacturing CDMO market, which are profiled in this report, include:- AGC Biologics
- Almac Group
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Catalent Inc.,
- Charles River Laboratories International Inc.
- Danaher Corporation
- Endress+Hauser Group Services AG
- FUJIFILM Diosynth Biotechnologies
- GC Corporation
- General Electric Company
- Getinge AB
- Infors AG
- Lonza Group Ltd
- Merck KGaA
- Miltenyi Biotec B.V. & Co. KG
- Patheon Inc.
- PCI Pharma Services
- Pfizer CentreOne
- PIERRE GUERIN
- Recipharm AB
- Samsung Biologics
- Sartorius AG
- Thermo Fisher Scientific
- uBriGene
- WuXi Advanced Therapies
- WuXi AppTec
Methodology
LOADING...
